Keyphrases
Heart Failure
84%
Heart Failure with Preserved Ejection Fraction (HFpEF)
50%
Patients with Heart Failure
35%
Confidence Interval
33%
Coronary Artery Disease
32%
ST-elevation Myocardial Infarction (STEMI)
30%
Metformin
25%
Type 2 Diabetes Mellitus (T2DM)
25%
Left Ventricular Remodeling
20%
Meta-analysis
20%
Desmosine
19%
All-cause Mortality
18%
Left Ventricular Hypertrophy
17%
Placebo
17%
Hazard Ratio
14%
Diabetes
14%
Hypertension
14%
Late Gadolinium Enhancement
13%
Inflammation
13%
Acute ST-segment Elevation Myocardial Infarction
13%
Echocardiography
13%
Chronic Heart Failure
13%
Pathophysiology
13%
Beta-blockers
12%
Prognostic Significance
12%
Heart Disease Diagnosis
12%
Odds Ratio
12%
Ejection Fraction
12%
Endothelial Dysfunction
12%
Patients with Diabetes
11%
Cardiac Magnetic Resonance Imaging (cMRI)
11%
Scotland
11%
Exercise-based Cardiac Rehabilitation
11%
Electronic Health Records
10%
Intramyocardial Hemorrhage
10%
Type 2 Diabetic Patients
10%
Elastin
10%
Tayside
10%
Incremental Prognostic Value
9%
Dapagliflozin
9%
Incident Heart Failure
9%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
9%
Ruptured Abdominal Aortic Aneurysm (rAAA)
9%
Survivors
9%
Heart Failure Treatment
9%
Systematic Meta-analysis
9%
Major Adverse Cardiovascular Events
9%
Dilated Cardiomyopathy
9%
Cardiovascular Disease
8%
Heart Failure Hospitalization
8%
Medicine and Dentistry
Congestive Heart Failure
98%
ST Segment Elevation Myocardial Infarction
30%
Cardiovascular Disease
28%
Coronary Artery Disease
26%
Maturity Onset Diabetes of the Young
24%
Cardiac Magnetic Resonance Imaging
23%
Biological Marker
21%
Heart Failure with Preserved Ejection Fraction
20%
Glycon
20%
Ejection Fraction
16%
Myocardial Infarction
16%
Diabetes
15%
Heart Failure with Reduced Ejection Fraction
15%
Echocardiography
15%
Cardiovascular System
15%
Cohort Analysis
14%
Left Ventricular Hypertrophy
14%
Gadolinium
13%
Placebo
13%
Meta-Analysis
13%
Infarction
13%
Systematic Review
12%
Pathophysiology
11%
Heart Ventricle Remodeling
11%
Desmosine
11%
Electronic Health Record
10%
Ischemic Heart Disease
10%
Odds Ratio
10%
Hazard Ratio
9%
Endothelial Dysfunction
9%
Patient with Diabetes
9%
Heart Rehabilitation
8%
Diseases
8%
Abdominal Aortic Aneurysm
8%
Aneurysm
8%
Aortic Stenosis
8%
Bleeding
8%
Atrial Fibrillation
7%
Obstruction
7%
Heart Left Ventricle Ejection Fraction
7%
Mendelian Randomization Analysis
6%
Elastin
6%
Patient with Type 2 Diabetes
6%
Coronary Angiography
6%
Diabetes Mellitus
6%
Cardiovascular Effect
6%
Loop Diuretic Agent
6%
Kidney Function
6%
Dilated Cardiomyopathy
6%
Adipose Tissue
6%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
ST Segment Elevation Myocardial Infarction
32%
Cardiovascular Disease
24%
Placebo
21%
Heart Failure with Reduced Ejection Fraction
21%
Metformin
20%
Heart Infarction
19%
Biological Marker
18%
Non Insulin Dependent Diabetes Mellitus
18%
Heart Ventricle Remodeling
17%
Cohort Study
16%
Inflammation
15%
Desmosine
14%
Bleeding
12%
Heart Left Ventricle Hypertrophy
12%
Coronary Artery Disease
12%
Dapagliflozin
12%
Pathophysiology
12%
Endothelial Dysfunction
11%
Infarction
11%
Heart Failure with Preserved Ejection Fraction
11%
Diseases
10%
Elastin
9%
Cardiovascular Risk
9%
Abdominal Aortic Aneurysm
9%
All Cause Mortality
9%
Obstruction
9%
Loop Diuretic Agent
8%
Diabetes Mellitus
8%
Randomized Controlled Trial
8%
Aneurysm
8%
Ischemic Heart Disease
7%
Atrial Fibrillation
6%
Beta Adrenergic Receptor Blocking Agent
6%
Cotransporter
6%
Diabetic Cardiomyopathy
5%
Acute Heart Infarction
5%
Diverticulosis
5%
Diverticulitis
5%
Nicorandil
5%
Sodium Glucose Cotransporter 2 Inhibitor
5%